BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20878117)

  • 1. Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.
    Bressan A; Bigioni M; Bellarosa D; Nardelli F; Irrissuto C; Maggi CA; Binaschi M
    Oncol Rep; 2010 Nov; 24(5):1249-55. PubMed ID: 20878117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
    Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
    Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity.
    Ieda N; Yamada S; Kawaguchi M; Miyata N; Nakagawa H
    Bioorg Med Chem; 2016 Jun; 24(12):2789-93. PubMed ID: 27143132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
    Xu WS; Perez G; Ngo L; Gui CY; Marks PA
    Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
    Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
    Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
    Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
    Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
    Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
    Conti C; Leo E; Eichler GS; Sordet O; Martin MM; Fan A; Aladjem MI; Pommier Y
    Cancer Res; 2010 Jun; 70(11):4470-80. PubMed ID: 20460513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
    Lobjois V; Frongia C; Jozan S; Truchet I; Valette A
    Eur J Cancer; 2009 Sep; 45(13):2402-11. PubMed ID: 19553104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
    Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
    J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
    Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
    Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
    J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.